Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Fudan University Shanghai Cancer Center Breast Cancer Precision Platform Series Study- Neoadjuvant Therapy (FASCINATE-N)

NCT05582499 is registered in ClinicalTrials.gov with Fudan University as lead sponsor.

NCT NCT05582499
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05582499 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Fudan University Shanghai Cancer Center Breast Cancer Precision Platform Series Study- Neoadjuvant Therapy (FASCINATE-N)
Lead sponsor
Fudan University
Phase
Phase 2
Overall status
Recruiting
Start date
November 1, 2022
Completion date
September 30, 2029
Enrollment
716 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

breast cancer, breast neoplasm, breast tumors, early-stage breast cancer, her2-negative breast cancer, her2-positive breast cancer, hormone receptor negative tumor, hormone receptor positive tumor, locally advanced breast cancer, triple-negative breast cancer (tnbc)